• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用组织型纤溶酶原激活剂治疗实验性玻璃体内纤维蛋白。

Treatment of experimental intravitreal fibrin with tissue plasminogen activator.

作者信息

Lambrou F H, Snyder R W, Williams G A, Lewandowski M

机构信息

Department of Ophthalmology, Medical College of Wisconsin, Milwaukee 53226.

出版信息

Am J Ophthalmol. 1987 Dec 15;104(6):619-23. doi: 10.1016/0002-9394(87)90175-9.

DOI:10.1016/0002-9394(87)90175-9
PMID:3120591
Abstract

We produced experimental intravitreal fibrin clots in rabbits that had previous gas compression of the vitreous or intact vitreous. Twenty-four hours after production of fibrin, the eyes were injected with 25 micrograms of tissue plasminogen activator or physiologic irrigation solution. In the gas compression group (n = 11), all tissue plasminogen activator-treated eyes cleared within six hours of injection; complete clearing was not seen until six days in the physiologic irrigation solution-treated eyes (n = 9). A similar response was seen in the intact vitreous group. No evidence of toxicity was observed as measured by slit-lamp biomicroscopy, intraocular pressure, corneal thickness, electroretinography, or histopathologic examination.

摘要

我们在先前有玻璃体气体压缩或玻璃体完整的兔子中制作了实验性玻璃体内纤维蛋白凝块。在产生纤维蛋白24小时后,向眼睛注射25微克组织型纤溶酶原激活剂或生理冲洗液。在气体压缩组(n = 11)中,所有接受组织型纤溶酶原激活剂治疗的眼睛在注射后6小时内凝块清除;而在接受生理冲洗液治疗的眼睛(n = 9)中,直到6天后才出现完全清除。在玻璃体完整组中也观察到类似的反应。通过裂隙灯生物显微镜检查、眼压测量、角膜厚度测量、视网膜电图或组织病理学检查均未观察到毒性证据。

相似文献

1
Treatment of experimental intravitreal fibrin with tissue plasminogen activator.用组织型纤溶酶原激活剂治疗实验性玻璃体内纤维蛋白。
Am J Ophthalmol. 1987 Dec 15;104(6):619-23. doi: 10.1016/0002-9394(87)90175-9.
2
Resolution of experimental intravitreal fibrin by tissue plasminogen activator.
Korean J Ophthalmol. 1990 Dec;4(2):58-65. doi: 10.3341/kjo.1990.4.2.58.
3
Intravitreal clearance of tissue plasminogen activator in the rabbit.兔眼玻璃体内组织型纤溶酶原激活剂的清除率
Arch Ophthalmol. 1988 Jul;106(7):969-72. doi: 10.1001/archopht.1988.01060140115036.
4
Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.用组织型纤溶酶原激活剂治疗实验性玻璃体出血。
Korean J Ophthalmol. 1990 Jun;4(1):12-5. doi: 10.3341/kjo.1990.4.1.12.
5
Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.组织型纤溶酶原激活剂的胶原盾递送:眼前段递送的功能和药代动力学研究
Refract Corneal Surg. 1992 Jan-Feb;8(1):44-8; discussion 48-53.
6
A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.一项关于兔玻璃体内注射组织型纤溶酶原激活剂后其扩散至视网膜下间隙能力的研究。
Am J Ophthalmol. 1999 Dec;128(6):739-46. doi: 10.1016/s0002-9394(99)00239-1.
7
Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.
Am J Ophthalmol. 1989 Aug 15;108(2):170-5. doi: 10.1016/0002-9394(89)90013-5.
8
Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.组织型纤溶酶原激活剂在犬眼内纤维蛋白溶解中的应用。
Am J Vet Res. 1992 Jun;53(6):894-6.
9
Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model.重组人组织型纤溶酶原激活剂的眼内纤维蛋白溶解作用。兔模型中的实验性治疗。
Arch Ophthalmol. 1987 Sep;105(9):1277-80. doi: 10.1001/archopht.1987.01060090135044.
10
Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).评价玻璃体内清除率和眼内注射氯诺昔康(xefo)的潜在视网膜毒性
J Ocul Pharmacol Ther. 2013 Sep;29(7):627-32. doi: 10.1089/jop.2012.0194. Epub 2013 Apr 4.

引用本文的文献

1
Subconjunctival hemorrhage: risk factors and potential indicators.结膜下出血:危险因素与潜在指标
Clin Ophthalmol. 2013;7:1163-70. doi: 10.2147/OPTH.S35062. Epub 2013 Jun 12.
2
Plasminogen in proliferative vitreoretinal disorders.增殖性玻璃体视网膜病变中的纤溶酶原
Br J Ophthalmol. 1997 Jul;81(7):590-4. doi: 10.1136/bjo.81.7.590.
3
Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator.
Int Ophthalmol. 1995;19(1):13-7. doi: 10.1007/BF00156413.
4
Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.影响抗生素治疗实验性术后眼内炎疗效的因素。
Trans Am Ophthalmol Soc. 1993;91:775-844.
5
Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.组织型纤溶酶原激活剂对玻璃体切除术后纤维蛋白形成的局部治疗
Int Ophthalmol. 1994;18(6):351-3. doi: 10.1007/BF00930313.
6
The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.白内障手术后前房内使用重组组织型纤溶酶原激活剂进行纤维蛋白溶解。
Int Ophthalmol. 1994;18(5):277-80. doi: 10.1007/BF00917830.
7
Treatment of experimental suprachoroidal hemorrhage with intravenous tissue plasminogen activator.
Int Ophthalmol. 1990 Jul;14(4):267-70. doi: 10.1007/BF00159862.
8
Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.玻璃体内注射重组组织型纤溶酶原激活剂治疗实验性诱导的细菌性眼内炎。
Int Ophthalmol. 1991 Mar;15(2):79-86. doi: 10.1007/BF01046426.